Open Access iconOpen Access

ARTICLE

crossmark

Apatinib reduces liver cancer cell multidrug resistance by modulating NF-κB signaling pathway

XIAOXIAO HE1, XUEQING ZHOU2, JINPENG ZHANG2, MINGFEI ZHANG2, DANHONG ZENG2, HENG ZHANG1, SHUCAI YANG2,*

1 Department of Gastroenterology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
2 Department of Clinical Laboratory, Pingshan Hospital, Southern Medical University (Pingshan District People’s Hospital of Shenzhen), Shenzhen, 518118, China

* Corresponding Author: SHUCAI YANG. Email: email

BIOCELL 2024, 48(9), 1331-1341. https://doi.org/10.32604/biocell.2024.052625

Abstract

Objectives: This investigation aimed to elucidate the inhibitory impact of apatinib on the multidrug resistance of liver cancer both in vivo and in vitro. Methods: To establish a Hep3B/5-Fu resistant cell line, 5-Fu concentrations were gradually increased in the culture media. Hep3B/5-Fu cells drug resistance and its alleviation by apatinib were confirmed via flow cytometry and Cell Counting Kit 8 (CCK8) test. Further, Nuclear factor kappa B (NF-κB) siRNA was transfected into Hep3B/5-Fu cells to assess alterations in the expression of multidrug resistance (MDR)-related genes and proteins. Nude mice were injected with Hep3B/5-Fu cells to establish subcutaneous xenograft tumors and then categorized into 8 treatment groups. The treatments included oxaliplatin, 5-Fu, and apatinib. In the tumor tissues, the expression of MDR-related genes was elucidated via qRT-PCR, immunohistochemistry, and Western blot analyses. Results: The apatinib-treated mice indicated slower tumor growth with smaller size compared to the control group. Both the in vivo and in vitro investigations revealed that the apatinib-treated groups had reduced expression of MDR genes GST-pi, LRP, MDR1, and p-p65. Conclusions: Apatinib effectively suppresses MDR in human hepatic cancer cells by modulating the expression of genes related to MDR, potentially by suppressing the NF-κB signaling pathway.

Keywords

Apatinib; Liver cancer; Multidrug resistance; NF-κB signaling pathway

Cite This Article

APA Style
HE, X., ZHOU, X., ZHANG, J., ZHANG, M., ZENG, D. et al. (2024). Apatinib reduces liver cancer cell multidrug resistance by modulating NF-κB signaling pathway. BIOCELL, 48(9), 1331–1341. https://doi.org/10.32604/biocell.2024.052625
Vancouver Style
HE X, ZHOU X, ZHANG J, ZHANG M, ZENG D, ZHANG H, et al. Apatinib reduces liver cancer cell multidrug resistance by modulating NF-κB signaling pathway. BIOCELL. 2024;48(9):1331–1341. https://doi.org/10.32604/biocell.2024.052625
IEEE Style
X. HE et al., “Apatinib reduces liver cancer cell multidrug resistance by modulating NF-κB signaling pathway,” BIOCELL, vol. 48, no. 9, pp. 1331–1341, 2024. https://doi.org/10.32604/biocell.2024.052625



cc Copyright © 2024 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1404

    View

  • 18541

    Download

  • 0

    Like

Share Link